Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study-Reference-Cited by-同舟云学术

Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study

Published:2024-05-07 Issue:9 Volume:65 Page:1281-1291
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ravandi Farhad¹,Subklewe Marion²³,Walter Roland B.⁴^ORCID,Vachhani Pankit⁵,Ossenkoppele Gert⁶,Buecklein Veit²³,Döhner Hartmut⁷,Jongen-Lavrencic Mojca⁸,Baldus Claudia D.⁹,Fransecky Lars⁹,Pardee Timothy S.¹⁰,Kantarjian Hagop¹^ORCID,Yen Priscilla K.¹¹,Mukundan Lata¹²,Panwar Bharat¹²,Yago Marc R.¹²,Agarwal Suresh¹¹,Khaldoyanidi Sophia K.¹¹,Stein Anthony¹³

Affiliation:

1. Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA

2. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany

3. Laboratory for Translational Research, Gene Center, LMU Munich, Munich, Germany

4. Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

5. Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

6. Amsterdam University Medical Center, Amsterdam, The Netherlands

7. Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

8. Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands

9. Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany

10. Department of Internal Medicine, Section on Hematology and Oncology, Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA

11. Amgen Inc, Thousand Oaks, CA, USA

12. Amgen Inc, South San Francisco, CA, USA

13. Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA, USA

Funder

Amgen Inc

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2346755

Reference30 articles.

1. National Cancer Institute Surveillance Epidemiology and End Results Program. SEER Cancer Statistics Review (CSR) 1975-2017. https://seer.cancer.gov/csr/1975_2017/. Accessed March 28 2023.

2. National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Leukemia–Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html. Accessed March 28 2023.

3. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

4. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

5. Acute Myeloid Leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia;Leukemia;2024-08-26

2. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells;Cellular Oncology;2024-07-15